4D Molecular Therapeutics, Inc. leadership

Co-founder of 4DMT; CEO and director since the company's inception in 2013 and President since January 2026. Former Executive Chairman until August 2020. Adjunct Professor of Bioengineering and Molecular & Cellular Biology at U.C. Berkeley and co-founder of the U.C. Berkeley Life Sciences Entrepreneurship Center. Previously co-founder and Executive Chairman of Ignite Immunotherapy and held senior development roles at Onyx Pharmaceuticals and Celgene.

Executive Chairman of the board since August 2020. Former President and CEO of Gilead Sciences (2016-2019) after 29 years at Gilead. Serves on the boards of Pacific Biosciences of California and Kailera Therapeutics.

Director since March 2019. CEO of ORIC Pharmaceuticals since May 2018; former CFO of Ignyta and investor at TPG Capital. Chairman of the board of Bright Peak Therapeutics.

Director since July 2020. Former EVP of Finance and Strategy of Royalty Pharma Management. Serves on the boards of AnaptysBio, Theravance Biopharma and Maravai LifeSciences.

Director since December 2015. Chief Medical Officer at Halozyme since October 2024; former President and CEO of Tracon Pharmaceuticals (2006-2024).

Director since November 2020. Pharmaceutical/biotech consultant and advisor since September 2017; previously a senior leader at Merck & Co. and Schering-Plough. Serves on the board of Aldeyra Therapeutics.

Director since November 2020. Former Chief Commercial Officer of Kite Pharma and Pharmacyclics; former CEO and board member of CoRegen. Serves on the board of Cabaletta Bio.

Director since January 2026 (Class I). Former CEO of IVERIC bio (until its 2023 acquisition by Astellas) and former President and CFO of The Medicines Company. Chair of the board of Mineralys Therapeutics and a director of Amicus Therapeutics.

Chief Financial Officer and Principal Financial Officer since November 2025 and Principal Accounting Officer since March 2026. Former CFO of Foghorn Therapeutics and CFO/Chief Business Officer of Viridian Therapeutics; previously Managing Director at Citigroup. Serves on the board of Sensei Biotherapeutics.

Chief Commercial and Business Officer since December 2025; previously Chief Commercial Officer from September 2024. Former Chief Commercial Officer at IVERIC bio and VP, Head of US Ophthalmics at Novartis.

Chief Legal Officer and Corporate Secretary since September 2021 and Chief Compliance Officer since December 2021. Former General Counsel at Synthego and Corporate Counsel at BioMarin Pharmaceutical.

Vice President, Finance & Controller since June 2024; served as Principal Financial Officer and Principal Accounting Officer from September 2025 until succeeded as Principal Accounting Officer by Kristian Humer in March 2026. Signs the 10-K as Principal Accounting Officer.

Joined as Chief Technical Officer in October 2018 and added Chief Operating Officer in February 2020; promoted to President and COO in September 2022. Resigned as President and COO effective December 31, 2025 and transitioned to a part-time Chief Technical Advisor role. Former SVP of Quality and Regulatory CMC at AveXis.

Appointed Chief Scientific Officer effective January 2, 2024, having joined the board as a Class I director in September 2022 (resigning from the board effective January 1, 2024). Professor and Alvera L. Kan Endowed Chair of Neurological Surgery and Radiation Oncology at UCSF with 30+ years in gene therapy.

Co-founder of 4DMT; served as Chief Scientific Advisor and director since inception in 2013 (per the S-1). Professor of Chemical and Biomolecular Engineering, Bioengineering, and Molecular and Cell Biology at U.C. Berkeley since 1999 and Director of the Berkeley Stem Cell Center since 2011; pioneered the application of directed evolution to the AAV capsid.

Chief Financial and Business Officer, Principal Financial Officer and Principal Accounting Officer from September 2023; resigned effective July 15, 2025, remaining as principal financial/accounting officer in an advisory capacity through September 2025. Former CFBO of Myovant Sciences and CFO of PACT Pharma and Proteus Digital Health.

Chief Financial Officer from January 2019 until his retirement effective September 11, 2023, continuing as a Senior Business Advisor and consultant. Former CFO of Assertio Therapeutics (Depomed) and Alexza Pharmaceuticals.

Chief Medical Officer since October 2020 (per the S-1). Former Chief Medical Officer of Xoc Pharmaceuticals and Corcept Therapeutics.